CN116635029A - Rev-erb激动剂 - Google Patents

Rev-erb激动剂 Download PDF

Info

Publication number
CN116635029A
CN116635029A CN202180076854.6A CN202180076854A CN116635029A CN 116635029 A CN116635029 A CN 116635029A CN 202180076854 A CN202180076854 A CN 202180076854A CN 116635029 A CN116635029 A CN 116635029A
Authority
CN
China
Prior art keywords
group
substituted
alkyl
atoms
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076854.6A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·K·沃克
托马斯·帕特里克·伯里斯
萨迪查·西陶拉
阿林丹姆·查特吉
拿破仑·克莱门特·达库尼亚
埃里克·乔恩·雅各布森
詹姆斯·罗伯特·布林恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paragas Pharmaceuticals
St Louis University
Original Assignee
Paragas Pharmaceuticals
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paragas Pharmaceuticals, St Louis University filed Critical Paragas Pharmaceuticals
Publication of CN116635029A publication Critical patent/CN116635029A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180076854.6A 2020-10-16 2021-10-15 Rev-erb激动剂 Pending CN116635029A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092893P 2020-10-16 2020-10-16
US63/092,893 2020-10-16
PCT/US2021/055165 WO2022093552A2 (en) 2020-10-16 2021-10-15 Rev-erb agonists

Publications (1)

Publication Number Publication Date
CN116635029A true CN116635029A (zh) 2023-08-22

Family

ID=81384462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076854.6A Pending CN116635029A (zh) 2020-10-16 2021-10-15 Rev-erb激动剂

Country Status (7)

Country Link
US (1) US20240002380A1 (https=)
EP (1) EP4228632A4 (https=)
JP (1) JP2023552490A (https=)
CN (1) CN116635029A (https=)
AU (1) AU2021372389A1 (https=)
CA (1) CA3195127A1 (https=)
WO (1) WO2022093552A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432302B (zh) * 2020-11-05 2024-08-27 中国科学院上海营养与健康研究所 小分子sr9009在抗衰老以及减轻衰老引起的慢性炎症中的用途
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途
WO2025024550A1 (en) * 2023-07-25 2025-01-30 University Of Florida Research Foundation, Incorporated Rev-erb antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472193A (en) * 1982-07-06 1984-09-18 The Dow Chemical Company Naphthyridinyloxy(or thio)phenoxy propanoic acids, derivatives thereof and methods of herbicidal use
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
BRPI0718161A2 (pt) * 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
WO2008144268A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
EP2417133A1 (en) * 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Compounds and methods for antiviral treatment
AU2011253058A1 (en) * 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2013033310A1 (en) * 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
US9586963B2 (en) * 2011-09-27 2017-03-07 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
US9266876B2 (en) * 2012-02-02 2016-02-23 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
ES2618004T3 (es) * 2012-08-07 2017-06-20 Merck Patent Gmbh Derivados de piridopirimidina como inhibidores de proteínas quinasas
JP2016505000A (ja) * 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2015103527A1 (en) * 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
ES2735087T3 (es) * 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
US11066396B2 (en) * 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
CN109776335B (zh) * 2017-11-15 2022-03-18 武汉尚赛光电科技有限公司 芘的胺类衍生物及其制备方法、应用和器件
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells

Also Published As

Publication number Publication date
AU2021372389A9 (en) 2024-02-08
WO2022093552A8 (en) 2023-05-11
AU2021372389A1 (en) 2023-05-11
WO2022093552A2 (en) 2022-05-05
WO2022093552A3 (en) 2022-10-06
EP4228632A2 (en) 2023-08-23
JP2023552490A (ja) 2023-12-15
EP4228632A4 (en) 2025-02-19
CA3195127A1 (en) 2022-05-05
WO2022093552A9 (en) 2022-06-23
US20240002380A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP5461525B2 (ja) Ｔｒｐｖ３モジュレーターとしての縮合ピリミジノン化合物
CN104540828B (zh) 作为ii组代谢型谷氨酸受体的别构调节剂的取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮
CN104470902B (zh) N‑(3‑杂芳基芳基)‑4‑芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
JP2023515728A (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
JP7539545B2 (ja) 複素環化合物及びその使用
CN116635029A (zh) Rev-erb激动剂
KR101407856B1 (ko) 에티닐 유도체
WO2012159565A9 (zh) 6-(芳基甲酰)咪唑并[1，2-a]嘧啶和6-(芳基甲酰)[1，2，4]三唑并[4，3-a]嘧啶作为Hedgehog通路抑制剂及其应用
WO2008003753A1 (en) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity
KR20160006207A (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
AU2021211437A1 (en) Novel cell metabolism modulating compounds and uses thereof
TWI644916B (zh) 哌喃并二吡啶化合物
CN118871432A (zh) 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物
WO2024028795A1 (en) Heterobicyclic compounds as oral glp1r agonists
KR20090127272A (ko) ｍＧｌｕＲ 리간드로서의 융합 피리미디논 화합물
CN114478537B (zh) 环酰胺并环化合物及其医药用途
JP2021519825A (ja) 輸送体の調節薬としての二環式エノンカルボキシラートとその使用
CN107759588A (zh) 一类苯基‑(吡唑并[1,5‑a]吡啶‑3‑基)甲酮衍生物
CN118591545B (zh) 一种调控15-pgdh活性的化合物及其制备方法
WO2016046404A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group iimetabotropic glutamate receptors
CN104744484A (zh) 一种3-呋喃[2,3-b]并吡啶-4-吲哚马来酰亚胺衍生物及其制备和应用
JP2009501176A (ja) グリコーゲンシンターゼキナーゼ３阻害薬としてのピリダジン化合物
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
CN119585282A (zh) 一种调控15-pgdh活性的化合物及其制备方法
CN121443609A (zh) 一种调控15-pgdh活性的化合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination